U.S. License Holder:
Eli Lilly Co.
Date of License:
December-17-2021; November-16-2022 (Interchangeable)
Last Update:
Sep-30-2024
FDA-Approved Indications
REZVOGLAR (insulin glargine-aglr) is a long-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.